Loading…
Employees: 2
Size Drugs Made In America Acquisition II (DMII) is a United States Financials company (Financial Conglomerates) with a market value of $650M, the 2536th largest of 3,117 United States companies the cockpit tracks. Shares closed at $10.21 on 6 Nov 2026.
Performance Over six months the shares gained 2.0%, against +0.1% for the median peer and -1.1% for the United States market (cap-weighted) — 6th highest of 19 in its peer set.
Short interest Short interest is 0.2% of the free float (15 Oct 2026).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | $0 | $0 | $0 |
| EBITDA | -$1.45M | -$1.30M | -$151,720 |
| Net income | $13.0M | $4.19M | -$151,719 |
| Free cash flow | -$1.28M | -$1.02M | -$194,300 |
| Capital expenditure | $0 | $0 | $0 |
| Total debt | $450,000 | $0 | $250,100 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DMII | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.2% | -0.1% | 9th highest of 21 |
| 6-month return | +2.0% | +0.1% | 6th highest of 19 |
| Distance from 52-week high | -1.2% | -12.1% | 3rd highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Drugs Made In America Acquisition II DMII | United States | $650M | +2% | n/a | n/a | n/a | n/a | n/a |
| Patrizia PAT.DE | Germany | $633M | -13% | +3% | -7% | n/a | n/a | n/a |
| OIO OIO | United States | $623M | -5% | -4% | -85% | n/a | n/a | n/a |
| Armada Acquisition Corp. II XRPN | United States | $608M | +2% | n/a | n/a | n/a | n/a | n/a |
| EQV Ventures Acquisition Corp. II EVAC | United States | $606M | +2% | n/a | n/a | n/a | n/a | n/a |
| Bain Capital GSS Investment BCSS | United States | $598M | +1% | n/a | n/a | n/a | n/a | n/a |
| Luyin Investment 600784.SS | China | $597M | -21% | +4% | 5% | n/a | n/a | n/a |
| Cantor Equity Partners IV CEPF | United States | $589M | 0% | n/a | n/a | n/a | n/a | n/a |
| Svolder SVOL-A.ST | Sweden | $721M | +35% | +1,360% | 90% | n/a | n/a | n/a |
| Bain Capital Specialty Finance BCSF | United States | $723M | -18% | -12% | 67% | n/a | n/a | n/a |
| Churchill Capital Corp XII CXII | United States | $575M | n/a | n/a | n/a | n/a | n/a | n/a |
| Senvest Capital SEC.TO | Canada | $762M | +18% | -18% | 628% | n/a | n/a | n/a |
| Metalla Royalty & Streaming MTA.V | Canada | $763M | +17% | +89% | 17% | n/a | n/a | n/a |
| Acceler8 Ventures AC8.L | United Kingdom | $546M | +5% | n/a | n/a | n/a | n/a | n/a |
| American Exceptionalism Acquisition AEXA | United States | $526M | -6% | n/a | n/a | n/a | n/a | n/a |
| MidCap Financial Investment MFIC | United States | $845M | -12% | +1% | 36% | n/a | n/a | n/a |
| New America Acquisition I NWAX | United States | $500M | 0% | n/a | n/a | n/a | n/a | n/a |
| RMR RMR | United States | $500M | -23% | -15% | 10% | n/a | n/a | n/a |
| Tangen Industrikapital TANGEN-B.ST | Sweden | $493M | n/a | +37% | 8% | n/a | n/a | n/a |
| Mountain Lake Acquisition Corp. II MLAA | United States | $491M | +2% | n/a | n/a | n/a | n/a | n/a |
| Ares Acquisition Corporation III AAC | United States | $490M | -6% | n/a | n/a | n/a | n/a | n/a |